Clinicopathological Significance of XXXX Expression in Cancer: a Meta-Analysis.

@entity1 @entity21158 @entity5 @entity3
BACKGROUND: Recent reports have shown that @entity21158 is widely expressed in normal tissues and is down- regulated in a wide range of @entity1 @entity5 , suggesting it may act as a @entity5 suppressor gene. We conducted a meta-analysis to determine the correlation between @entity21158 expression and clinicopathological characteristics in @entity5 . MATERIALS AND METHODS: A detailed literature search was made for relevant publications from PubMed, EMBASE, Cochrane library databases, Web of Science, CNKI. The methodological quality of the studies was also evaluated. Analyses of pooled data were performed and odds ratios (ORs) were calculated and summarized. RESULTS: Final analysis was performed of 1,815 @entity5 @entity1 from 19 eligible studies. We observed that @entity21158 expression was significantly lower in @entity5 than in normal tissues. @entity21158 expression was not found to be associated with @entity5 differentiation status. However, @entity21158 expression was obviously lower in advance stage than in early-stage @entity5 and was more down-regulated in metastatic than non-metastatic @entity5 . CONCLUSIONS: The results of our meta-analysis suggested that @entity21158 expression is significantly lower in @entity5 than in normal tissues. Aberrant @entity21158 expression may play an important role in @entity5 genesis and @entity3 .
